Chang Ho Ahn
Directeur/Membre du Conseil chez TheraTarget, Inc.
Postes actifs de Chang Ho Ahn
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
TheraTarget, Inc.
 TheraTarget, Inc. Pharmaceuticals: MajorHealth Technology TheraTarget, Inc. develops innovative polymer therapeutics for the treatment of cancer. It is a biopharmaceutical drug delivery company developing a variety of polymer-drug conjugates utilizing our nanopolymer drug delivery technologies. The company was founded in October 2008 and is headquartered in Salt Lake, UT. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Chang Ho Ahn
Anciens postes connus de Chang Ho Ahn
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| REXAHN PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 22/06/2015 | 31/08/2017 |
| Président | 01/05/2005 | 22/06/2015 | |
| Directeur Technique/Scientifique/R&D | 08/03/2011 | - | |
| Fondateur | 19/03/2001 | 31/08/2017 | |
| President | 01/05/2005 | 05/02/2013 | |
| Rexahn Corp. | Directeur Général | 01/03/2001 | 01/05/2005 |
| Président | 01/03/2001 | 01/05/2005 | |
| The Society of Biomedical Research | President | 01/01/2000 | 01/01/2003 |
| Center for Drug Evaluation & Research | Corporate Officer/Principal | 01/01/1988 | 01/01/2001 |
Formation de Chang Ho Ahn
| The Ohio State University | Doctorate Degree |
| Creighton University | Undergraduate Degree |
| Seoul National University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 8 |
| Corée du Sud | 2 |
Opérationnelle
| Director/Board Member | 2 |
| Chairman | 2 |
| President | 2 |
Sectorielle
| Consumer Services | 4 |
| Health Technology | 3 |
| Government | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Rexahn Pharmaceuticals, Inc.
 Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | Health Technology |
| The Society of Biomedical Research | |
| Center for Drug Evaluation & Research | Government |
| Rexahn Corp. | Finance |
TheraTarget, Inc.
TheraTarget, Inc. Pharmaceuticals: MajorHealth Technology TheraTarget, Inc. develops innovative polymer therapeutics for the treatment of cancer. It is a biopharmaceutical drug delivery company developing a variety of polymer-drug conjugates utilizing our nanopolymer drug delivery technologies. The company was founded in October 2008 and is headquartered in Salt Lake, UT. | Health Technology |
- Bourse
- Insiders
- Chang Ho Ahn
- Expérience
